Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001837772 | SCV000284762 | benign | Hypercholesterolemia, autosomal dominant, type B; Familial hypobetalipoproteinemia 1 | 2024-08-21 | criteria provided, single submitter | clinical testing | |
Gene |
RCV002466475 | SCV002762348 | uncertain significance | not provided | 2022-06-08 | criteria provided, single submitter | clinical testing | In silico analysis supports that this missense variant does not alter protein structure/function; Has not been previously published as pathogenic or benign to our knowledge |
Fulgent Genetics, |
RCV001837772 | SCV002789513 | uncertain significance | Hypercholesterolemia, autosomal dominant, type B; Familial hypobetalipoproteinemia 1 | 2021-08-17 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV003165602 | SCV003856466 | uncertain significance | Cardiovascular phenotype | 2022-12-18 | criteria provided, single submitter | clinical testing | The p.A4483V variant (also known as c.13448C>T), located in coding exon 29 of the APOB gene, results from a C to T substitution at nucleotide position 13448. The alanine at codon 4483 is replaced by valine, an amino acid with similar properties. This amino acid position is conserved. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |